We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

7 hedge funds and large institutions have $67K invested in Carisma Therapeutics in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.62% less ownership

Funds ownership: 7.36% → 3.75% (-3.6%)

79% less funds holding

Funds holding: 33 → 7 (-26)

92% less capital invested

Capital invested by funds: $843K → $67K (-$776K)

93% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 28

Holders
7
Holders Change
-26
Holders Change %
-78.79%
% of All Funds
0.09%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
2
Increased
1
Reduced
–
Closed
28
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$10K
2
BBA
Baader Bank Aktiengesellschaft
Germany
+$4.89K
3
UBP
Union Bancaire Privee
Switzerland
+$63

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$96K
2
BlackRock
BlackRock
New York
-$92.3K
3
Renaissance Technologies
Renaissance Technologies
New York
-$80.5K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$68.7K
5
State Street
State Street
Massachusetts
-$23.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
MC
1
Merck & Co
New Jersey
$63.3K – – –
XT
2
XTX Topco
Cayman Islands
$1.72K +$10K +40,097 New
EF
3
Empowered Funds
Pennsylvania
$1.33K – – –
BBA
4
Baader Bank Aktiengesellschaft
Germany
$517 +$4.89K +19,515 New
UBP
5
Union Bancaire Privee
Switzerland
$28 +$63 +250 +47%
IA
6
IFP Advisors
Florida
$9 – – –
OP
7
ORG Partners
Indiana
$8 – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
– -$96K -350,324 Closed
BlackRock
9
BlackRock
New York
– -$92.3K -336,789 Closed
Renaissance Technologies
10
Renaissance Technologies
New York
– -$80.5K -293,686 Closed
Geode Capital Management
11
Geode Capital Management
Massachusetts
– -$68.7K -250,495 Closed
State Street
12
State Street
Massachusetts
– -$23.3K -85,106 Closed
Northern Trust
13
Northern Trust
Illinois
– -$15.1K -55,039 Closed
GS
14
GTS Securities
New York
– -$13.7K -50,118 Closed
BCM
15
Bridgeway Capital Management
Texas
– -$8.49K -30,988 Closed
BWA
16
Blodgett Wealth Advisors
California
– -$6.58K -24,001 Closed
VF
17
Virtu Financial
New York
– -$6K -22,854 Closed
Goldman Sachs
18
Goldman Sachs
New York
– -$4.5K -16,410 Closed
DFG
19
Dynamic Financial Group
Iowa
– -$4.21K -15,350 Closed
TSS
20
Two Sigma Securities
New York
– -$3.52K -12,828 Closed
Citigroup
21
Citigroup
New York
– -$3.09K -11,274 Closed
UBS Group
22
UBS Group
Switzerland
– -$1.93K -7,032 Closed
Morgan Stanley
23
Morgan Stanley
New York
– -$873 -3,185 Closed
Group One Trading
24
Group One Trading
Illinois
– -$611 -2,230 Closed
Bank of America
25
Bank of America
North Carolina
– -$383 -1,398 Closed
1
2

CARM Hedge Fund Activity: Q4 2025 in Review

7 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2025, worth a combined $67K — down 92% from $843K a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CARM and 2 opened new positions — a net loss of 26 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was XTX Topco, opening a new position worth an estimated $10K. The largest seller was Vanguard Group, exiting entirely with an estimated $96K sold.

  • 7 institutional investors held Carisma Therapeutics (CARM) as of Q4 2025, down from 33 in Q3 2025.
  • Funds reported $67K of Carisma Therapeutics stock for Q4 2025, down 92% quarter-over-quarter.
  • 2 funds opened new Carisma Therapeutics positions in Q4 2025 and 28 closed out, a net change of -26 holders.
  • The largest Carisma Therapeutics buyer in Q4 2025 was XTX Topco, an estimated $10K added.
  • The largest Carisma Therapeutics seller in Q4 2025 was Vanguard Group, an estimated $96K sold.

Based on aggregated 13F filings for Q4 2025.